Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment–Naive Patients with COPD in the US
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
3.04
Funders
Boehringer Ingelheim
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment–Naive Patients with COPD in the US
Jerome Ritz, Brendan Clark, Julian Casciano, Asif Shaikh et al.
Citations
2 citations
Journal
International Journal of COPD
Topics
Chronic Obstructive Pulmonary Disease (COPD) Research
Field-Weighted Citation Impact (FWCI)
3.04
article
Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment–Naive Patients with COPD in the US
Jerome Ritz, Brendan Clark, Julian Casciano, Asif Shaikh, Jennifer Kathleen Quint, Zenobia Dotiwala, Swetha Palli
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
International Journal of COPDVol. Volume 20
Institutions
Delray Medical Center (US), Boehringer Ingelheim (France) (FR), Boehringer Ingelheim (United States) (US), Imperial College London (GB)
Funders
Boehringer Ingelheim
OpenAlex Percentile
Openalex Percentile: Top 11%
Topics
Chronic Obstructive Pulmonary Disease (COPD) Research